CytomX Therapeutics AI Stock Analysis
Want to see CTMX full AI Analyst Report?
CytomX Therapeutics (CTMX) AI Stock Analysis
CytomX Therapeutics
(NASDAQ:CTMX)
The score is held down primarily by weak financial performance (declining TTM revenue, sizable losses, and materially negative free cash flow indicating continued cash burn) and bearish technicals (price below key moving averages with negative MACD and weak momentum). These are partially offset by a constructive earnings call centered on advancing Varseta-M toward a potential registrational study, improving diarrhea management in optimization cohorts, and a projected cash runway into the second half of 2028.
CytomX Therapeutics (CTMX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $444.73M
- Dividend Yield
- ―
- Average Volume (3M)
- 4.20M
- Price to Earnings (P/E)
- -4.5
- Beta (1Y)
- 2.98
- Revenue Growth
- -87.66%
- EPS Growth
- -210.45%
- Country
- US
- Employees
- 69
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
CytomX Therapeutics Business Overview & Revenue Model
Company Description
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncologi...
How the Company Makes Money
CytomX primarily makes money through (1) collaboration and licensing arrangements and (2) to the extent achieved, development-related payments tied to partnered programs. Under these partnerships, CytomX can earn upfront payments (when agreements are...
CytomX Therapeutics Earnings Call Summary
The call was predominantly positive, with management highlighting progress toward a potential first registrational study for Varseta-M in the first half of 2027, encouraging progression-free survival, improved Grade 3 diarrhea results in dose optimization, expanding combination and pan-tumor programs, continued CX-801 enrollment, and cash runway into the second half of 2028. These positives were tempered by lower revenue following the Astellas collaboration conclusion, higher operating expenses, ongoing gastrointestinal toxicity management, and the delay of the monotherapy update to January.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
CytomX expects to move Varseta-M monotherapy into a potential registrational study in the first half of 27, with an integrated update in January including the first look at overall survival, which is anticipated to be the primary endpoint in the initial registrational study; the bevacizumab combination is expected to report initial clinical data in the first half of 27, while the Varseta-M combination with bevacizumab, 5-fluorouracil and leucovorin is expected to start by the end of the year as a new Phase 1/2 trial, initially enrolling most likely late stage patients before the phase 2 part enrolls second line patients once phase 1 dose finding is successfully completed. CytomX has initiated gastrointestinal cohorts in unselected gastric and gastroesophageal junction cancer, EpCAM selected pancreatic ductal adenocarcinoma and EpCAM selected biliary tract cancer, with an initial plan to enroll approximately 20 patients per tumor type, and expects to report initial CX-801 melanoma data in the first half of 27. The company’s goal is to manage grade 3 diarrhea to 20% or below, and it projects cash runway into the second half of 28.
CytomX Therapeutics Financial Statement Overview
Summary
Overall fundamentals are weak: TTM revenue is down meaningfully (~-23%) and profitability has swung back to a large net loss after a profitable 2024, indicating high volatility. Cash generation is a major concern with materially negative TTM operating cash flow and free cash flow (about -$50M each), implying ongoing cash burn. The balance sheet helps somewhat with low reported leverage (debt-to-equity ~0.02), but inconsistent/occasionally negative equity and negative returns in TTM remain key risks.
Income Statement
28NegativeBalance Sheet
54NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.03M | 76.20M | 138.10M | 101.21M | 53.16M | 37.31M |
| Gross Profit | 13.78M | 76.20M | 138.10M | 101.21M | 53.16M | 37.31M |
| EBITDA | -87.53M | -15.75M | 33.86M | 5.50M | -96.87M | -113.16M |
| Net Income | -85.42M | -17.37M | 31.87M | -569.00K | -99.32M | -115.87M |
Balance Sheet | ||||||
| Total Assets | 364.68M | 151.57M | 120.53M | 201.79M | 260.89M | 339.41M |
| Cash, Cash Equivalents and Short-Term Investments | 347.98M | 137.05M | 100.62M | 174.51M | 193.65M | 305.23M |
| Total Debt | 4.39M | 4.24M | 9.38M | 13.97M | 18.06M | 21.67M |
| Total Liabilities | 79.79M | 52.56M | 120.99M | 249.24M | 346.64M | 339.87M |
| Stockholders Equity | 284.89M | 99.01M | -456.00K | -47.45M | -85.75M | -459.00K |
Cash Flow | ||||||
| Free Cash Flow | -51.00M | -75.81M | -86.54M | -56.88M | -112.53M | -120.64M |
| Operating Cash Flow | -50.21M | -75.59M | -86.23M | -56.03M | -110.79M | -119.03M |
| Investing Cash Flow | -201.25M | -59.74M | 99.70M | -150.67M | 98.26M | 22.49M |
| Financing Cash Flow | 251.74M | 110.45M | 7.52M | 30.23M | 648.00K | 110.21M |
CytomX Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTMX, the sentiment is Negative. The current price of 2.04 is below the 20-day moving average (MA) of 2.24, below the 50-day MA of 2.56, and below the 200-day MA of 3.71, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 39.35 is Neutral, neither overbought nor oversold. The STOCH value of 35.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTMX.
CytomX Therapeutics Risk Analysis
CytomX Therapeutics disclosed 74 risk factors in its most recent earnings report. CytomX Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksCytomX Therapeutics Peers Comparison
Overall Rating
ARCT54Neutral
VSTM54Neutral
BCYC50Neutral
LXRX46Neutral
CTMX45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 54Neutral | $240.96M | -2.70 | -46.79% | ― | -74.84% | -25.04% | |
| 54Neutral | $1.03B | -4.42 | -359.49% | ― | 649.65% | 54.01% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $235.88M | -1.66 | -26.02% | ― | 194.79% | 43.93% | |
| 46Neutral | $796.97M | -12.32 | -38.44% | ― | -45.62% | 21.16% | |
| 45Neutral | $444.73M | -4.52 | -33.97% | ― | -87.66% | -210.45% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CTMX | CytomX Therapeutics Inc. | 2.04 | -1.51 | -42.54% | |
| LXRX | Lexicon Pharmaceuticals | 1.79 | 0.33 | 22.60% | |
| VSTM | Verastem Inc | 8.18 | -0.97 | -10.60% | |
| ARCT | Arcturus Therapeutics | 8.36 | 1.60 | 23.67% | |
| BCYC | Bicycle Therapeutics | 3.37 | -3.09 | -47.83% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
